Trials / Completed
CompletedNCT02454010
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.
Detailed description
The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors. This is an open label study that will recruit approx 70 patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | FF21101 | (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene) |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2021-10-01
- Completion
- 2021-10-01
- First posted
- 2015-05-27
- Last updated
- 2025-04-04
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02454010. Inclusion in this directory is not an endorsement.